サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1470730

過体重治療市場：製品タイプ別、エンドユーザー別、地域別 - 世界の産業分析、規模、シェア、成長、動向、予測、2024年～2031年

Overweight Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日
ページ情報
英文 245 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
過体重治療市場：製品タイプ別、エンドユーザー別、地域別 - 世界の産業分析、規模、シェア、成長、動向、予測、2024年～2031年
出版日: 2024年04月24日
発行: Persistence Market Research
ページ情報: 英文 245 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の過体重治療市場を包括的に分析し、その成長促進要因・課題・新興動向に関する洞察を提供しています。この詳細なレポートでは、2024年から2031年までの市場の軌跡を予測する独自のデータと統計を提供しています。

主な洞察

  • 市場規模（2024年）：412億米ドル
  • 予測市場価値（2031年）：741億米ドル
  • 世界市場成長率（2024年～2031年のCAGR）：7.8%

過体重治療市場 - 調査範囲

過体重治療市場は、世界中で増大する肥満と過体重状態の懸念に対処し、体重管理と全体的な健康状態を改善するための様々な治療介入、ライフスタイルの改善、外科的処置を提供します。座りっぱなしのライフスタイル、不健康な食習慣、代謝異常の増加に伴い、肥満は世界の流行病となっており、効果的な治療ソリューションへの需要が高まっています。この市場には、体重管理と肥満予防を目的とした医薬品、医療機器、外科手術、生活習慣への介入が含まれます。

市場成長の促進要因：

肥満や過体重の有病率の増加と、過体重に伴う健康リスクに対する意識の高まりが、過体重治療ソリューションの需要を世界的に牽引しています。食生活の乱れ、運動不足、ストレスなどの生活習慣が肥満の蔓延を助長しており、体重管理療法や介入策の市場拡大をもたらしています。さらに、肥満の予防と治療を目的とした政府の取り組み、公衆衛生キャンペーン、償還政策が市場の成長をさらに刺激しています。

市場の抑制要因：

過体重治療ソリューションに対する認識と需要は高まっていますが、いくつかの課題が市場の成長を阻害しています。これには、医療サービスが行き届いていない地域におけるヘルスケアサービスへのアクセスの制限、肥満の有病率における社会経済的格差、健康的なライフスタイルの採用に対する文化的障壁などが含まれます。さらに、肥満にまつわる偏見や、体重管理が医学的な問題ではなく美容的な問題であるという認識は、医療提供者や政策立案者が肥満の流行に効果的に対処する上での課題となっています。

市場機会：

進化する過体重治療の状況は、ヘルスケア、医薬品、栄養、フィットネスなど、様々な分野にわたる革新と協力の機会を提示しています。医療技術の進歩に伴い、遺伝的、代謝的、行動的要因を治療戦略に取り入れた体重管理への個別化アプローチに注目が集まっています。さらに、デジタルヘルスソリューション、ウェアラブルデバイス、遠隔医療プラットフォームの統合により、肥満管理プログラムへのアクセシビリティと関与が強化され、市場拡大の新たな機会が生まれています。

本レポートで扱う主な質問

  • 過体重治療市場の成長を促進する主な要因は何か？
  • 技術の進歩は肥満管理と減量介入をどのように形成しているか？
  • 市場成長を阻害する主な課題は何か、またどのように対処できるか？
  • 過体重治療市場で大きな成長が見込まれる地域はどこか？
  • 市場の主要利害関係者は誰で、肥満の蔓延に対処するためにどのような戦略を採用しているのか？

競合情報と事業戦略：

過体重治療市場の主要企業は、肥満管理の複雑な課題に対処するため、技術革新、調査、戦略的提携に注力しています。製薬会社は肥満に関連する代謝障害をターゲットとした新規治療薬の開発に投資し、医療機器メーカーは低侵襲減量手技のための先進機器を導入します。さらに、ヘルスケアプロバイダーは、ウェルネス団体、栄養士、フィットネスの専門家と協力して、個々のニーズに合わせた包括的な体重管理プログラムを提供しています。

主な企業プロファイル：

  • Novo Nordisk A/S
  • Roche Holding AG
  • GlaxoSmithKline plc
  • Medtronic plc
  • Johnson & Johnson Services, Inc.
  • Allergan plc
  • Abbott Laboratories
  • Pfizer Inc.
  • Amgen Inc.
  • Merck & Co., Inc.

過体重治療市場調査セグメンテーション：

治療別の過体重治療市場

  • 薬物治療
  • ブプロピオンとナルトレキソン
  • オルリスタット
  • フェンテルミンとトピラマート
  • リラグルチド
  • その他
  • サプリメント
  • 医療機器/インプラント
  • 胃バルーン
  • 胃バンド
  • ステープリング器具

過体重治療市場：流通チャネル別

  • 施設販売
  • 病院
  • 専門クリニック
  • 外来手術センター
  • 小売販売
  • 小売薬局
  • ドラッグストア
  • スーパーマーケット／ハイパーマーケット
  • ヘルス＆ビューティーストア
  • オンライン販売

地域別の過体重治療市場

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • イノベーション/開発動向

第4章 主要な成功要因

  • 製品採用分析
  • 国別の肥満率
  • 過体重治療薬パイプライン分析
  • 肥満薬離脱分析
  • 過体重治療薬・医療機器の撤回、臨床試験の中止
  • 規制シナリオ
  • メーカーの主なプロモーション戦略
  • ポーターの分析
  • PESTEL分析

第5章 COVID-19危機分析

  • COVID-19の現在の統計と今後の影響の可能性
  • 現在のGDP予測と予想される影響
  • 2008年と比較した現在の経済予測経済分析
  • COVID-19と影響分析
    • 収益：治療別
    • 収益：流通チャネル別
    • 収益：国別

第6章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第7章 世界の過体重治療市場の需要分析（2019年～2023年）と予測（2024年～2031年）

  • 過去の市場価値分析（2019年～2023年）
  • 現在および将来の市場価値予測（2024年～2031年）
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界の過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）：治療別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析（2019年～2023年）：治療別
  • 現在および将来の市場規模分析と予測（2024年～2031年）：治療別
    • 薬物治療
    • サプリメント
    • 医療機器/ インプラント
  • 治療方法別の市場魅力度分析

第9章 世界の過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）：流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析（2019年～2023年）：流通チャネル別
  • 現在および将来の市場規模分析と予測（2024年～2031年）：流通チャネル別
    • 施設販売
    • 小売販売
    • オンライン販売
  • 流通チャネル別の市場魅力度分析

第10章 世界の過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）：地域別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析（2019年～2023年）：地域別
  • 現在および将来の市場規模分析と予測（2024年～2031年）：地域別
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別の市場魅力度分析

第11章 北米の過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）

第12章 ラテンアメリカの過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）

第13章 欧州の過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）

第14章 東アジアの過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）

第15章 南アジアの過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）

第16章 オセアニアの過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）

第17章 中東・アフリカの過体重治療市場分析（2019年～2023年）と予測（2024年～2031年）

第18章 市場構造分析

  • 企業階層別の市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第19章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Novo Nordisk A/S
    • VIVUS LLC
    • AstraZeneca
    • Currax Pharmaceuticals LLC.
    • Spansules Pharmatech Pvt Ltd
    • Atkins Nutritional Inc.
    • Apollo Endosurgery, Inc.
    • Herbalife Nutrition Ltd.
    • SMP Nutra
    • Allurion Technologies
    • ReShape Lifesciences, Inc.
    • Bariatric Solutions GmbH
    • Silimed
    • ENDALIS
    • Districlass Medical
    • Medtronic

第20章 前提と頭字語

第21章 調査手法

目次
Product Code: PMRREP33086

Persistence Market Research presents a comprehensive analysis of the global overweight treatment market, providing insights into its growth drivers, challenges, and emerging trends. This detailed report offers exclusive data and statistics projecting the market's trajectory from 2024 to 2031.

Key Insights:

  • Market Size (2024E): US$41.2 Billion
  • Projected Market Value (2031F): US$74.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2031): 7.8%

Overweight Treatment Market - Report Scope:

The overweight treatment market addresses the growing concern of obesity and overweight conditions worldwide, offering various therapeutic interventions, lifestyle modifications, and surgical procedures to manage weight and improve overall health. With the rise in sedentary lifestyles, unhealthy dietary habits, and metabolic disorders, obesity has become a global epidemic, driving demand for effective treatment solutions. The market encompasses pharmaceuticals, medical devices, surgical procedures, and lifestyle interventions aimed at weight management and obesity prevention.

Market Growth Drivers:

The increasing prevalence of obesity and overweight conditions, coupled with rising awareness about the health risks associated with excess weight, drives the demand for overweight treatment solutions globally. Lifestyle factors such as poor diet, lack of physical activity, and stress contribute to the obesity epidemic, creating a growing market for weight management therapies and interventions. Additionally, government initiatives, public health campaigns, and reimbursement policies aimed at obesity prevention and treatment further stimulate market growth.

Market Restraints:

Despite the growing awareness and demand for overweight treatment solutions, several challenges hinder market growth. These include limited access to healthcare services in underserved regions, socioeconomic disparities in obesity prevalence, and cultural barriers to adopting healthy lifestyles. Moreover, the stigma associated with obesity and the perception of weight management as a cosmetic issue rather than a medical concern pose challenges for healthcare providers and policymakers in addressing the obesity epidemic effectively.

Market Opportunities:

The evolving landscape of overweight treatment presents opportunities for innovation and collaboration across various sectors, including healthcare, pharmaceuticals, nutrition, and fitness. With advancements in medical technology, there is a growing focus on personalized approaches to weight management, incorporating genetic, metabolic, and behavioral factors into treatment strategies. Furthermore, the integration of digital health solutions, wearable devices, and telemedicine platforms enhances accessibility and engagement in obesity management programs, creating new opportunities for market expansion.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the overweight treatment market?
  • How are technological advancements shaping the landscape of obesity management and weight loss interventions?
  • What are the key challenges hindering market growth, and how can they be addressed?
  • Which regions are expected to witness significant growth in the overweight treatment market?
  • Who are the key stakeholders in the market, and what strategies are they adopting to address the obesity epidemic?

Competitive Intelligence and Business Strategy:

Leading players in the overweight treatment market focus on innovation, research, and strategic partnerships to address the complex challenges of obesity management. Pharmaceutical companies invest in the development of novel therapeutics targeting obesity-related metabolic disorders, while medical device manufacturers introduce advanced devices for minimally invasive weight loss procedures. Moreover, healthcare providers collaborate with wellness organizations, nutritionists, and fitness professionals to offer comprehensive weight management programs tailored to individual needs.

Key Companies Profiled:

  • Novo Nordisk A/S
  • Roche Holding AG
  • GlaxoSmithKline plc
  • Medtronic plc
  • Johnson & Johnson Services, Inc.
  • Allergan plc
  • Abbott Laboratories
  • Pfizer Inc.
  • Amgen Inc.
  • Merck & Co., Inc.

Overweight Treatment Market Research Segmentation:

Overweight Treatment Market by Treatment:

  • Drug Treatment
  • Bupropion and Naltrexone
  • Orlistat
  • Phentermine and Topiramate
  • Liraglutide
  • Others
  • Supplements
  • Medical Devices / Implants
  • Gastric Balloons
  • Gastric Bands
  • Stapling Devices

Overweight Treatment Market by Distribution Channel:

  • Institutional Sales
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Retail Sales
  • Retail Pharmacy
  • Drug Stores
  • Supermarkets / Hypermarkets
  • Health & Beauty Stores
  • Online Sales

Overweight Treatment Market by Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Technology Roadmap
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption Analysis
  • 4.2. Obesity Rate by Country
  • 4.3. Obesity Drugs Pipeline Analysis
  • 4.4. Obesity Drug Withdrawal Analysis
  • 4.5. Obesity Drug / Device Withdrawal, Termination from Clinical Trials
  • 4.6. Regulatory Scenario
  • 4.7. Key Promotional Strategies by Manufacturers
  • 4.8. Porter's Analysis
  • 4.9. PESTEL Analysis

5. COVID19 Crisis Analysis

  • 5.1. Current COVID19 Statistics and Probable Future Impact
  • 5.2. Current GDP Projection and Probable Impact
  • 5.3. Current Economic Projection as compared to 2008 Economic analysis
  • 5.4. COVID-19 and Impact Analysis
    • 5.4.1. Revenue by Treatment
    • 5.4.2. Revenue by Distribution Channel
    • 5.4.3. Revenue by Country

6. Market Background

  • 6.1. Macro-Economic Factors
    • 6.1.1. Global GDP Growth Outlook
    • 6.1.2. Per-Capita Healthcare Expenditure
  • 6.2. Forecast Factors - Relevance & Impact
    • 6.2.1. COVID-19 Pandemic
    • 6.2.2. Increasing Prevalence of Obesity
    • 6.2.3. Rise in R&D Investments
    • 6.2.4. Top Overweight Treatment Companies and Their Historical Growth
    • 6.2.5. Rise in Number of Clinical Studies
    • 6.2.6. Increasing Investment in Obesity Research
    • 6.2.7. GDP Growth
    • 6.2.8. Adoption Rate of Overweight Treatment Products
  • 6.3. Market Dynamics
    • 6.3.1. Drivers
    • 6.3.2. Restraints
    • 6.3.3. Opportunity Analysis

7. Global Overweight Treatment Market Demand (in Value or Size in US$ MN) Analysis 2019-2023 and Forecast, 2024-2031

  • 7.1. Historical Market Value (US$ MN) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ MN) Projections, 2024-2031
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Treatment

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis by Treatment, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Treatment, 2024-2031
    • 8.3.1. Drug Treatment
      • 8.3.1.1. Bupropion and Naltrexone
      • 8.3.1.2. Orlistat
      • 8.3.1.3. Phentermine and Topiramate
      • 8.3.1.4. Liraglutide
      • 8.3.1.5. Others
    • 8.3.2. Supplements
    • 8.3.3. Medical Devices / Implants
      • 8.3.3.1. Gastric Balloons
      • 8.3.3.2. Gastric Bands
      • 8.3.3.3. Stapling Devices
  • 8.4. Market Attractiveness Analysis by Treatment

9. Global Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Distribution Channel, 2024-2031
    • 9.3.1. Institutional Sales
      • 9.3.1.1. Hospitals
      • 9.3.1.2. Specialty Clinics
      • 9.3.1.3. Ambulatory Surgical Centers
    • 9.3.2. Retail Sales
      • 9.3.2.1. Retail Pharmacy
      • 9.3.2.2. Drug Stores
      • 9.3.2.3. Supermarkets/ Hypermarkets
      • 9.3.2.4. Health & Beauty Stores
    • 9.3.3. Online Sales
  • 9.4. Market Attractiveness Analysis by Distribution Channel

10. Global Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031, by Region

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2024-2031
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Treatment
    • 11.3.3. By Distribution Channel
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Treatment
    • 11.4.3. By Distribution Channel
  • 11.5. Market Trends
  • 11.6. Key Market Participants - Intensity Mapping
  • 11.7. Drivers and Restraints - Impact Analysis
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Overweight Treatment Market Analysis
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Treatment
        • 11.8.1.2.2. By Distribution Channel
    • 11.8.2. Canada Overweight Treatment Market Analysis
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Treatment
        • 11.8.2.2.2. By Distribution Channel

12. Latin America Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
        • 12.3.1.4.1. By Treatment
        • 12.3.1.4.2. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Treatment
    • 12.4.3. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Overweight Treatment Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Treatment
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Brazil Overweight Treatment Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Treatment
        • 12.8.2.2.2. By Distribution Channel
    • 12.8.3. Argentina Overweight Treatment Market Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Treatment
        • 12.8.3.2.2. By Distribution Channel

13. Europe Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Nordic Countries & Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Treatment
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Treatment
    • 13.4.3. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Overweight Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Treatment
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Italy Overweight Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Treatment
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. France Overweight Treatment Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Treatment
        • 13.8.3.2.2. By Distribution Channel
    • 13.8.4. U.K. Overweight Treatment Market Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Treatment
        • 13.8.4.2.2. By Distribution Channel
    • 13.8.5. Spain Overweight Treatment Market Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Treatment
        • 13.8.5.2.2. By Distribution Channel
    • 13.8.6. BENELUX Overweight Treatment Market Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Treatment
        • 13.8.6.2.2. By Distribution Channel
    • 13.8.7. Nordic Countries & Russia Overweight Treatment Market Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Treatment
        • 13.8.7.2.2. By Distribution Channel

14. East Asia Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
        • 14.3.1.3.1. By Treatment
        • 14.3.1.3.2. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Treatment
    • 14.4.3. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Overweight Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Treatment
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. Japan Overweight Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Treatment
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. South Korea Overweight Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Treatment
        • 14.8.3.2.2. By Distribution Channel

15. South Asia Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Philippines
      • 15.3.1.5. Thailand
      • 15.3.1.6. Vietnam
      • 15.3.1.7. Rest of South Asia
    • 15.3.2. By Treatment
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Treatment
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Overweight Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Treatment
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Indonesia Overweight Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Treatment
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. Malaysia Overweight Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Treatment
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Philippines Overweight Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Treatment
        • 15.8.4.2.2. By Distribution Channel
    • 15.8.5. Thailand Overweight Treatment Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Treatment
        • 15.8.5.2.2. By Distribution Channel
    • 15.8.6. Vietnam Overweight Treatment Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Treatment
        • 15.8.6.2.2. By Distribution Channel

16. Oceania Overweight Treatment Market 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Treatment
    • 16.3.3. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Treatment
    • 16.4.3. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Overweight Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Treatment
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. New Zealand Overweight Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Treatment
        • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Overweight Treatment Market Analysis 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Israel
      • 17.3.1.3. Turkey
      • 17.3.1.4. South Africa & North Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Treatment
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Treatment
    • 17.4.3. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Overweight Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Treatment
        • 17.8.1.2.2. By Distribution Channel
    • 17.8.2. Israel Overweight Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Treatment
        • 17.8.2.2.2. By Distribution Channel
    • 17.8.3. Turkey Overweight Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Treatment
        • 17.8.3.2.2. By Distribution Channel
    • 17.8.4. South Africa & North Africa Overweight Treatment Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Treatment
        • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis
    • 18.3.1. Regional footprint of Players
    • 18.3.2. Channel Foot Print by Players

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Benchmarking
  • 19.3. Competition Deep Dive
    • 19.3.1. Novo Nordisk A/S
      • 19.3.1.1. Overview
      • 19.3.1.2. Product Portfolio
      • 19.3.1.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.1.4. Sales Footprint
      • 19.3.1.5. Strategy Overview
      • 19.3.1.6. SWOT Analysis
    • 19.3.2. VIVUS LLC
      • 19.3.2.1. Overview
      • 19.3.2.2. Product Portfolio
      • 19.3.2.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.2.4. Sales Footprint
      • 19.3.2.5. Strategy Overview
      • 19.3.2.6. SWOT Analysis
    • 19.3.3. AstraZeneca
      • 19.3.3.1. Overview
      • 19.3.3.2. Product Portfolio
      • 19.3.3.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.3.4. Sales Footprint
      • 19.3.3.5. Strategy Overview
      • 19.3.3.6. SWOT Analysis
    • 19.3.4. Currax Pharmaceuticals LLC.
      • 19.3.4.1. Overview
      • 19.3.4.2. Product Portfolio
      • 19.3.4.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.4.4. Sales Footprint
      • 19.3.4.5. Strategy Overview
      • 19.3.4.6. SWOT Analysis
    • 19.3.5. Spansules Pharmatech Pvt Ltd
      • 19.3.5.1. Overview
      • 19.3.5.2. Product Portfolio
      • 19.3.5.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.5.4. Sales Footprint
      • 19.3.5.5. Strategy Overview
      • 19.3.5.6. SWOT Analysis
    • 19.3.6. Atkins Nutritional Inc.
      • 19.3.6.1. Overview
      • 19.3.6.2. Product Portfolio
      • 19.3.6.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.6.4. Sales Footprint
      • 19.3.6.5. Strategy Overview
      • 19.3.6.6. SWOT Analysis
    • 19.3.7. Apollo Endosurgery, Inc.
      • 19.3.7.1. Overview
      • 19.3.7.2. Product Portfolio
      • 19.3.7.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.7.4. Sales Footprint
      • 19.3.7.5. Strategy Overview
      • 19.3.7.6. SWOT Analysis
    • 19.3.8. Herbalife Nutrition Ltd.
      • 19.3.8.1. Overview
      • 19.3.8.2. Product Portfolio
      • 19.3.8.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.8.4. Sales Footprint
      • 19.3.8.5. Strategy Overview
      • 19.3.8.6. SWOT Analysis
    • 19.3.9. SMP Nutra
      • 19.3.9.1. Overview
      • 19.3.9.2. Product Portfolio
      • 19.3.9.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.9.4. Sales Footprint
      • 19.3.9.5. Strategy Overview
      • 19.3.9.6. SWOT Analysis
    • 19.3.10. Allurion Technologies
      • 19.3.10.1. Overview
      • 19.3.10.2. Product Portfolio
      • 19.3.10.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.10.4. Sales Footprint
      • 19.3.10.5. Strategy Overview
      • 19.3.10.6. SWOT Analysis
    • 19.3.11. ReShape Lifesciences, Inc.
      • 19.3.11.1. Overview
      • 19.3.11.2. Product Portfolio
      • 19.3.11.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.11.4. Sales Footprint
      • 19.3.11.5. Strategy Overview
      • 19.3.11.6. SWOT Analysis
    • 19.3.12. Bariatric Solutions GmbH
      • 19.3.12.1. Overview
      • 19.3.12.2. Product Portfolio
      • 19.3.12.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.12.4. Sales Footprint
      • 19.3.12.5. Strategy Overview
      • 19.3.12.6. SWOT Analysis
    • 19.3.13. Silimed
      • 19.3.13.1. Overview
      • 19.3.13.2. Product Portfolio
      • 19.3.13.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.13.4. Sales Footprint
      • 19.3.13.5. Strategy Overview
      • 19.3.13.6. SWOT Analysis
    • 19.3.14. ENDALIS
      • 19.3.14.1. Overview
      • 19.3.14.2. Product Portfolio
      • 19.3.14.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.14.4. Sales Footprint
      • 19.3.14.5. Strategy Overview
      • 19.3.14.6. SWOT Analysis
    • 19.3.15. Districlass Medical
      • 19.3.15.1. Overview
      • 19.3.15.2. Product Portfolio
      • 19.3.15.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.15.4. Sales Footprint
      • 19.3.15.5. Strategy Overview
      • 19.3.15.6. SWOT Analysis
    • 19.3.16. Medtronic
      • 19.3.16.1. Overview
      • 19.3.16.2. Product Portfolio
      • 19.3.16.3. Key Financials by Market Segments (Product/Channel/Region)
      • 19.3.16.4. Sales Footprint
      • 19.3.16.5. Strategy Overview
      • 19.3.16.6. SWOT Analysis

20. Assumptions and Acronyms Used

21. Research Methodology